Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) (2014 - 2026)
Pacific Biosciences Of California (PACB) recorded quarterly EPS (Weighted Average and Diluted) of -$0.03 in Q1 2026, up 76.92% quarter-over-quarter from -$0.13 in Q4 2025, and up 97.92% on a YoY basis from -$0.02 in Q1 2025.
Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) (2014 - 2026) Analysis & Trends
Pacific Biosciences Of California's EPS (Weighted Average and Diluted) history runs 11 years deep, the most recent figure standing at -$0.03 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 97.92% year-over-year to -$0.03; the TTM figure through Mar 2026 stood at -$0.43 (up 84.31% YoY), while the FY2025 annual figure was -$1.82, down 14.47% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.03 for Q1 2026 at Pacific Biosciences Of California, up from -$0.13 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q1 2026 to a low of -$1.44 in Q1 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.36 across 5 years, with a median of -$0.31 in 2023.
- The sharpest annual moves came in 2025 and 2026: EPS (Weighted Average and Diluted) tumbled 396.55% in 2025, then surged 97.92% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.37 in 2022, then grew by 16.22% to -$0.31 in 2023, then slumped by 41.94% to -$0.44 in 2024, then jumped by 70.45% to -$0.13 in 2025, then jumped by 76.92% to -$0.03 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.03 (Q1 2026), -$0.13 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 0.61 |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 1.93 |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 0.89 |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 0.90 |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 0.66 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 0.51 |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 0.85 |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 2.24 |
| 10 | Pacific Biosciences Of California | 426.62 Mn | 150.66 Mn | 12.84 Mn | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.03 |
| Dec 31, 2025 | -0.13 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.14 |
| Mar 31, 2025 | -1.44 |
| Dec 31, 2024 | -0.44 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -0.64 |
| Mar 31, 2024 | -0.29 |
| Dec 31, 2023 | -0.31 |
| Sep 30, 2023 | -0.26 |
| Jun 30, 2023 | -0.28 |
| Mar 31, 2023 | -0.36 |
| Dec 31, 2022 | -0.37 |
| Sep 30, 2022 | -0.34 |
| Jun 30, 2022 | -0.32 |
| Mar 31, 2022 | -0.37 |
| Dec 31, 2021 | -0.33 |
| Jun 30, 2021 | -0.21 |
| Mar 31, 2021 | -0.45 |